Statistics

Introduction

As immunotherapy has emerged as a central pillar in cancer treatment, the discovery of putative tumor antigens continues to accelerate. While their immunogenicity can be experimentally assessed, a major challenge remains: the lack of rapid and reliable methods to evaluate the tumor specificity of these antigens across diverse normal tissues. This gap limits clinical translation due to the risk of on-target, off-tumor toxicity.

TuttiPepti offers a pragmatic web-service for assessing the tumor-specificity of peptide antigens across normal tissues. By enabling rapid and large-scale evaluations, it supports safer and more informed prioritization of immunotherapeutic targets.